Nabriva Therapeutics (NASDAQ: NBRV)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-04 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.190 | -0.200 | -0.0100 | ||||
REV | 9.570M | 8.020M | -1.550M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Nabriva Therapeutics (NASDAQ: NBRV) through any online brokerage.
There are no as such competitors for Nabriva Therapeutics.
The latest price target for Nabriva Therapeutics (NASDAQ: NBRV) was reported by Northland Capital Markets on Wednesday, March 30, 2022. The analyst firm set a price target for 2.00 expecting NBRV to rise to within 12 months (a possible 880.39% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Nabriva Therapeutics (NASDAQ: NBRV) is $0.204 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Nabriva Therapeutics.
Nabriva Therapeutics’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for Nabriva Therapeutics.
Nabriva Therapeutics is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.